Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, announced it has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.
With this acquisition, Cambrex will enter the large and growing market for early stage small molecule development and testing services. The acquisition strengthens Cambrex’s position as the leading fully integrated small molecule contract development and manufacturing organization (CDMO). Completion of the transaction is expected during the fourth quarter of 2018.
Avista operates four facilities located in Durham, Longmont, Agawam (UK) and Edinburgh (Scotland, UK). All sites have a strong reputation for quality and excellent regulatory track records. The company offers a broad suite of scientifically differentiated services ranging from early stage discovery, API and Drug Product development and cGMP manufacturing to stand-alone analytical and microbiology testing support. Avista has worked on more than 200 small molecules for approximately 180 customers so far in 2018, providing some combination of analytical testing, early stage process chemistry, formulation development, manufacturing, or solid state chemistry services.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers APIs, finished dosage forms, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Headquartered in East Rutherford (USA), Cambrex has cGMP manufacturing facilities in the USA (Charles City), Europe (Sweden, Italy), India, and R&D centers in Tallinn (Estonia), Wiesbaden (Germany).